Evaluation of the Effect of ACA1 on Gastric adenocarcinoma:

Phase 3

Recruiting

• Conditions: Gastric adenocarcinoma.; Malignant neoplasm of stomach

• Registration Number: IRCT20200626047927N1
• Lead Sponsor: Shahed University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 August 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Patients with gastric adenocarcinoma whose disease has been confirmed histologically, are in the metastatic stage and at least two common chemotherapy treatments have been administered to them and the disease is not under control.
Adequate bone marrow function: 40001500, Plt>100000, Hb>8
Adequate liver function: Total Bill>1.5, AST&ALT<100
Adequate kidney function: Cr<1.5
performance status=1

Exclusion Criteria

positive serology for HIV, HBV, HCV
Metastasis to CNS
other malignancies

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Quality of Life. Timepoint: Start of study (before the start of the intervention) and one month after the start of ACA1 consumption. Method of measurement: EORTC-QLQ-30 Standard questionnaire.

Secondary Outcome Measures

Name	Time	Method
White Blood Cell Count. Timepoint: Start studying (before starting the intervention) and one month after starting ACA1 consumption. Method of measurement: Cell Counter.;Hemoglobin. Timepoint: Start studying (before starting the intervention) and one month after starting ACA1 consumption. Method of measurement: Cell Counter.;Platelet Count. Timepoint: Start studying (before starting the intervention) and one month after starting ACA1 consumption. Method of measurement: Cell Counter.;Body Mass Index. Timepoint: Start studying (before starting the intervention) and one month after starting ACA1 consumption. Method of measurement: Meter and scale.